(3.236.100.86) 您好!臺灣時間:2021/05/07 09:42
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:陳泓道
研究生(外文):Hung-Tao Chen
論文名稱:女貞子和半胱氨酸衍生物對高脂飲食小鼠體內肥胖相關賀爾蒙的影響
論文名稱(外文):The Effects of Ligustrum Lucidum Fructus and Cysteine-containing Agents upon Obesity Associated Hormones in Mice Consumed High Fat Diet
指導教授:殷梅津殷梅津引用關係
學位類別:碩士
校院名稱:中國醫藥大學
系所名稱:營養學系碩士班
學門:醫藥衛生學門
學類:營養學類
論文種類:學術論文
論文出版年:2009
畢業學年度:97
語文別:中文
論文頁數:56
中文關鍵詞:女貞子胰島素肥胖
外文關鍵詞:Ligustrum lucidum Aitinsulinobesity
相關次數:
  • 被引用被引用:0
  • 點閱點閱:169
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
女貞子為木樨科植物-Ligustrum Lucidum Ait之乾燥果實。它在中醫藥理上有補腎滋陰,養肝明目、強心、健腰膝、滋養通便、鎮痛解熱、安神清虛弱。在中國自古以來就是大眾愛用的提神、強壯體力之藥。半胱氨酸衍生物為大蒜之水溶性含硫化合物。本實驗的目的在探討女貞子及半胱氨酸衍生物對高脂飲食小鼠體內肥胖相關賀爾蒙的影響,以及女貞子水粹之抗肥胖功效。本實驗將女貞子水粹和兩種半胱氨酸衍生物s-propyl-L-cysteine (SPC)、s-allyl-L-cysteine (SAC)分別添加至小鼠飲水中。在10週實驗飲食後犧牲,採集小鼠血液、肝臟、腎臟、心臟、副睪脂肪等,檢測女貞子水粹液和半胱氨酸衍生物對於小鼠體內脂肪組織、insulin、leptin、resistin和ghrelin等肥胖相關賀爾蒙的影響。結果顯示攝取高濃度女貞子水粹與SPC之小鼠體重、副睪脂肪重、血清insulin、leptin、resistin皆明顯降低。女貞子與SPC對於肥胖小鼠有使身體脂肪減少並減輕因肥胖造成leptin resistance效應的保護作用。而實驗結果也發現給予低濃度、高濃度女貞子與SAC之小鼠血清resistin濃度顯著地降低,這也說明了投與女貞子可以改善高油飲食之小鼠血清中高resistin的狀況。這可能是因為女貞子與半胱氨酸衍生物先改善了leptin resistance,進而緩和resistin濃度的上升。這些結果支持女貞子水粹液、SAC、SPC可以減少體脂肪的囤積及影響相關賀爾蒙分泌。
Glossy privet fruit (Ligustrum lucidum Ait, GPF) is a common edible plant in Asian countries. It is used as a herb for traditional Chinese medicine. It has been reported that this fruit possesses anti-oxidative, anti-inflammatory,hepatoprotective, and anti-aging activities. S-propyl- L-cysteine (SPC) and S-allyl-L-cysteine (SAC) are two hydrophilic cysteine-containing compounds naturally formed in Allium plants such as garlic and onion. The major purpose of this study was to evaluate the in vivo effect of SAC, SPC and aqueous extract of GPF on variation of hormones associated with obesity development in mice consuming a high fat diet. The impact of these agents on body weight, the plasma level of insulin, leptin, resistin, ghrelin and the weight of epididymis was determined.
The diet with 18% saturated fat significantly increased body weight and epididymal weight; and significantly elevated insulin, leptin and resistin levels in serum (P<0.05). However, the treatments from SPC and GPF (high dose) significantly reduced high fat diet-caused insulin, leptin and resistin levels in serum; and also significantly lowered body weight, epididymal weight and oxidative stress (P<0.05). It has been reported that abdominal obesity led to insulin and/or leptin resistance and increased resistin secretion. However, this present study found that SPC and GPF might alleviate leptin resistance, which further attenuated resistin elevation. These results support that Ligustrum lucidum Ait and SPC are potential agents for reducing body fat and affecting obesity associated hormones.
目次 ……………………………………………………………………….……….. i
圖表目次……………………………………………………………….…………… iv
中文摘要……………………………………………………………….…………… 1
英文摘要……………………………………………………………….…………… 2
第一章 前言……………………………………………………………….……….. 3
第二章 文獻探討……………………………………………………………….….. 4
一、肥胖之成因………………………………………………………………. 4
二、肥胖對健康的影響………………………………………………………. 5
三、肥胖之相關賀爾蒙………………………………………………………. 5
(一) Insulin……………………………………………………………….. 5
(二) Leptin………………………………………………………………... 6
(三) 胰島素與瘦體素之交互作用………………………………………. 7
(四) Resistin………………………………………………………………. 7
(五) Ghrelin………………………………………………………………. 9
四、女貞子與肥胖……………………………………………………………. 9
(一)女貞子簡介……………………………………………………………. 9
(二)女貞子之活性化合物之抗肥胖功效…………………………………. 10
五、半胱氨酸衍生物與肥胖…………………………………………………. 10
第三章 材料與方法…………………………………………………. ……………. 12
一、實驗材料………………………………………………………………………. 12
(一) 實驗動物…………………………………………………………………… 12
(二) 化學試藥…………………………………………………………………… 12
1.特殊飲水用藥……………………………………………………………….. 12
2.特殊飲食…………………………………………………………………….. 12
3.實驗分析試藥:…………………………………………………………….. 13
(三)分析檢驗套組……………………………………………………………….. 13
(四) 儀器設備…………………………………………………………………… 14
二、實驗方法………………………………………………………………………. 15
(一) 實驗動物…………………………………………………………………. 15
(二) 實驗設計…………………………………………………………………. 15
(三) 動物血液與臟器之收集…………………………………………………. 17
(四) 組織液之處理……………………………………………………………. 17
三、實驗分析……………………………………………………………………… 18
(一) 血清胰島素(Insulin) 濃度測定………………………………………… 18
(二) 總蛋白質(Total protein)濃度測定……………………………………… 19
(三)  血清Ghrelin濃度測定………………………………………………….. 22
(四)  血清Leptin濃度測定…………………………………………………… 24
(五)  血清Resistin濃度測定………………………………………………….. 26
(六)  脂質氧化脂丙二醛(Malondialdehyde;MDA) 濃度測定……………... 28
四、統計方法……………………………………………. ………………………... 30
第四章 結果…………………………………………………. ……………………. 31
一、每日飲水量……………………………………………………………… 31
二、小鼠體重變化…………………………………………………………… 31
三、小鼠副睪脂肪重量之變化……………………………………………… 31
四、小鼠臟器秤重…………………………………………………………… 32
五、小鼠血清中MDA 濃度之變化………………………………………… 32
六、小鼠血清中Insulin 濃度之變化……………………………………….. 32
七、小鼠血清中Leptin 濃度之變化………………………………………… 32
八、小鼠血清中Resistin 濃度之變化………………………………………. 33
九、小鼠血清中Ghrelin 濃度之變化………………………………………. 33
第五章 討論……………………………………………………………………….. 43
一、女貞子水粹對高脂飲食小鼠之抗肥胖功效………………………………… 43
二、半胱氨酸衍生物對高脂飲食小鼠之抗肥胖功效…………………………… 44
三、女貞子水粹及半胱氨酸衍生物對高脂飲食小鼠體內肥胖相關賀爾蒙的影響 45
1. Insulin ……………………………………………………………………… 46
2. Leptin ……………………………………………………………………… 47
3. Resistin …………………………………………………………………….. 47
4.Ghrelin ……………………………………………………………………… 48
第六章 結論……………………………………………………………………….. 50
第七章 參考文獻………………………………………………………………….. 51

圖表目次
頁次
表2.1、 Diet induce obesity (DIO)高脂飲食成分表……………………………. 16
圖3.1、 高脂飲食小鼠飲水中添加高濃度女貞子、低濃度女貞子、SAC與SPC(1g/L) 十週後,小鼠每日之飲水量 34
表3.1、 高脂飲食小鼠飲水中添加高濃度女貞子、低濃度女貞子、SAC與SPC(1g/L) 十週後的體重 35
圖3.2、 高脂飲食小鼠飲水中添加高濃度女貞子、低濃度女貞子、SAC與
SPC(1g/L) 十週後的小鼠副睪脂肪重量…………………….………… 36
表3.2、 高脂飲食小鼠飲水中添加高濃度女貞子、低濃度女貞子、SAC與
SPC(1g/L) 十週後肝臟、腎臟與心臟重量。…………………………. 37
圖3.3、 高脂飲食小鼠飲水中添加高濃度女貞子、低濃度女貞子、SAC與
SPC(1g/L) 十週的小鼠肝臟MDA濃度。……………………………. 38
圖3.4、 高脂飲食小鼠飲水中添加高濃度女貞子、低濃度女貞子、SAC與
SPC(1g/L) 十週後小鼠血清Insulin之濃度。………………………… 39
圖3.5、 高脂飲食小鼠飲水中添加高濃度女貞子、低濃度女貞子、SAC與
SPC(1g/L) 十週後小鼠血清中Leptin的濃度。………………………. 40
圖3.6、 高脂飲食小鼠飲水中添加高濃度女貞子、低濃度女貞子、SAC與
SPC(1g/L) 十週後小鼠血清中Resistin的濃度。…………………….. 41
圖3.7、 在高脂飲食小鼠飲水中添加高濃度女貞子、低濃度女貞子、SAC與
SPC(1g/L) 十週,對於小鼠血清中Ghrelin濃度之影響。…………… 42
[1]Seidell, J.C. & Rissanen, A.M. Time trends in the worldwide prevalence of obesity. Handbook of obesity. 1998;119-150.
[2] Bjorntrorp P. Obesity. Lancet. 1997;423-426.
[3]行政院衛生署98年度重要社會發展計畫先期作業計畫書,2009。
[4]Garrow, J.S. Health implications of obesity. Obesity and related diseases. Churchill Livingstone. 1988;1-16.
[5]Gidding, S.S. A perspective on obesity. Am J Med Sci. 1995;310:68-71.
[6]Bray GA, York DA. Hypothalamic and genetic obesity in experimental animals: an automonia and endocrine hypothesis. Physiol Rev. 1979;59:719-809.
[7]Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974; 32: 77-97.
[8]Bogardus C, Lillioja S, Ravussin E. Familial dependence of the resting metabolic rate. N Engl J Med. 1986; 315:96-100.
[9]Bouchard C, Tremblay A. Genetic effects in human energy expenditure components. Int J Obes. 1990; 14: 49-58.
[10]Weinsier RL, Hunter GR, Heini AF. The etiology of obesity :Relative contribution of metabolic factors, diet, and physical activity. Am J Med. 1998; 105:145-50.
[11]Goran MI, Shewchuk R, Gower BA, Nagy TR, Carpenter WH, Johnson RK. Longitudinal changes in fatness in white children : no effect of childhood energy expenditure. Am J Cli Nutr. 1998; 67: 309-316.
[12]Heini AF, Weinsier RL. Divergent trends in obesity and fat intake patterns: the American paradox. Am J Med. 1997; 102:259-264.
[13]Barness LA, Opitz JM, Gilbert-Barness E. Obesity: genetic, molecular, and environmental aspects. Am J Med Genet. 2007;24:3016-34.
[14]Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States. JAMA. 2004;291(10):1238-45
[15]Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA. 1999; 282(16): 1530-8.
[16]Manson JE, Willett WC, Stampfer MJ. Body weight and mortality among women. N Engl J Med. 1995; 333(11):677-85.
[17]Haslam DW, James WP. Obesity. Lancet. 2005; 366(9492):1197-209
[18]Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L. Obesity in adulthood and its consequences for life expectancy : a life-table analysis. Ann Intern Med. 2003; 138(1):24-32.
[19]Ganong WF. Review of medical physiology. Twentieth Ed. McGraw-HillBook Co. 2001;322-343.
[20]Hadley ME. Endocrinology, fifth Ed. Prentice hall international Inc. 2000; 268-271.
[21]Zhang Y, Proenca R, Maffei M. Positional cloning of the mouse obese gene and its human analogue. Nature. 1994; 372:425-432.
[22]Jequier E, Tappy L. Regulation of body weight in humans. Physiol Rev. 1999; 79: 451-480.
[23]O. Moran and M. Phillip. Leptin: obesity, diabetes and other peripheral effects. Pediatric Diabetes. 2003; 4: 101-109.
[24]Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T , Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995; 269:540-543.
[25]Levin N, Nelson C, Gurney A, Vandlen R, Sauvage F. Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proc Nat Acad Sci. 1996; 93:1726-1730.
[26]Bagdade JD, Bierman EL, Porte DJ. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nodiabetic subjects. J Clin Invest.1967; 46:1549-1557.
[27]Considine RV, Sinha MK, Kolaczynski JW, Heiman ML. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334: 292-295.
[28]Baura GD, Foster DM, Porte DJ, Kahn SE, Bergman RN, Cobelli C , Schwartz MW. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest. 1993; 92:1824-1830.
[29]Baskin DG, Wilcox BJ, Figlewicz DP. Insulin and insulin-like growth factors in the CNS. Trends Neurosci. 1988; 11:107- 111.
[30]Weigle DS Bukowski T.R. Foster DC, Holderman S, Kramer JM, Lasser G. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J Clin Invest. 1995; 96: 2065-2070.
[31]Michael WS, Stephen CW, Daniel PJ, Randy JS ,Denis GB. Central nervous system control of food intake. Nature. 2000; 404: 661-671.
[32]Woods SC, Seeley RJ, Porte DJ, Schwartz MW. Signalsthat regulate food intake and energy homeostasis. Science. 1998; 280: 1378-1383.
[33]Philip G. McTernan, Christine M. Kusminski and Sudhesh Kumar. Resistin. Curr Opin Lipidol. 2006; 17:170-175.
[34]V?嚎quez-Vela ME, Torres N, Tovar AR. White adipose tissue as endocrine organ and its role in obesity. Arch Med Res. 2008; 39(8):715-28.
[35]Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004; 50(9):1511-25.
[36]Ukkola O. Resistin-a mediator of obesity-associated insulin resistance or an innocent bystander. Eur J Endocrinol. 2002; 147:571-4.
[37]Wang G, Lee HM, Englander E, Greeley GH Jr. Ghrelin—not just another stomach hormone. Regul Pept. 2002; 105:75-81.
[38]Qi X, Reed JT, Wang G, Han S, Englander EW, Greeley GH Jr. Ghrelin secretion is not reduced by increased fat mass during diet-induced obesity. Am J Physiol Regul Integr Comp Physiol. 2008; 295(2):429-35.
[39]Wang ZH, Hsu CC, Yin MC. Antioxidative characteristics of aqueous and ethanol extracts of glossy privet fruit. Food Chem. 2009; 112: 914-918.
[40]He ZD, But PPH, Chan TW, Dong H, Xu HX, Lau CP, Sun HD. Antioxidative glucosides from the fruits of Ligustrum lucidum. Chem Pharm Bull. 2001; 49(6):780-4.
[41]Yin MC, Chan KC. Nonenzymatic antioxidative and antiglycative effects of oleanolic acid and ursolic acid. J Agric Food Chem. 2007; 55(17):7177-81.
[42]Yunoki K, Sasaki G, Tokuji Y, Kinoshita M, Naito A, Aida K, Ohnishi M. Effect of dietary wine pomace extract and oleanolic acid on plasma lipids in rats fed high-fat diet and its DNA microarray analysis. J Agric Food Chem. 2008; 56(24):12052-8.
[43]Jayaprakasam B, Olson LK, Schutzki RE, Tai MH, Nair MG. Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry. J Agric Food Chem. 2006; 54(1):243-8.
[44]Block E. The chemistry of garlic and onions. Sci Am. 1985; 252: 94-99.
[45]Cavallito CJ, Bailey JH. Allicin, the antibacterial principle of
allium sativum. I. Isolation,physical properties and antibacterial action. J Am Chem Soc. 1944; 66:1950-1951.
[46]Kawasaki M, Funabiki R, Yagasaki K. Effects of dietary methionine and cystine on lipid metabolism in hepatoma-bearing rats with hyper- lipidemia. Lipids. 1998; 33(9):905-11.
[47]Lin CC, Yin MC, Hsu CC, Lin MP. Effect of five cysteine-containing compounds on three lipogenic enzymes in Balb/cA mice consuming a high saturated fat diet. Lipids. 2004; 39(9):843-8.
[48]Lin CC, Yin MC. Effects of cysteine-containing compounds on biosynthesis of triacylglycerol and cholesterol and anti-oxidative protection in liver from mice consuming a high-fat diet. Brit J Nutr. 2008 ;99(1):37-43.
[49]van Gaal LF, Zhang A, Steijaert MM, De Leeuw IH. Human obesity: from lipid abnormalities to lipid oxidation. Int J Obes Relat Metab Disord. 1995;19:21-26.
[50]Hsu CC, Yen HF, Yin MC, Tsai CM, Hsieh CH. Five cysteine-containing compounds delay diabetic deterioration in Balb/cA mice. J Nutr. 2004; 134(12):3245-9.
[51]Hsu CC, Lin CC, Liao TS, Yin MC. Protective effect of s-allyl cysteine and s-propyl cysteine on acetaminophen-induced hepatotoxicity in mice. Food Chem Toxicol. 2006;44(3):393-7.
[52]D''Aquino M, Benedetti PC, Di Felice M, Gentili V, Tomassi G, Maiorino M, Ursini F. Effect of fish oil and coconut oil on antioxidant defence system and lipid peroxidation in rat liver. Free Radic Res Commun. 1991; 12-13:147-52.
[53]Wellen KE, Uysal KT, Wiesbrock S, Yang Q, Chen H, Hotamisligil GS. Interaction of tumor necrosis factor-alpha- and thiazolidinedione- regulated pathways in obesity. Endocrinology. 2004 ;145(5):2214-20.
[54]Tamori Y, Kasuga M. Obesity and insulin resistance. Nippon Rinsho. 2009 ;67(2):236-44.
[55]Liu H, Shi Y, Wang D, Yang G, Yu A, Zhang H. MECC determination of oleanolic acid and ursolic acid isomers in Ligustrum lucidum Ait. J Pharm Biomed Anal. 2003;32(3):479-85.
[56]Gao D, Li Q. Antidiabetic and antioxidant effects of oleanolic acid from ligustrum lucidum ait in alloxan-induced diabetic rats. Phytotherapy Research. 2009; Mar 9.(Epub)
[57]Baratta M. Leptin - from a signal of adiposity to a hormone mediator in peripheral tissues. Med Sci Mon. 2002; 8(12):282-92.
[58]Sandhofer A, Laimer M, Ebenbichler CF, Kaser S, Paulweber B, Patsch JR. Soluble leptin receptor and soluble receptor-bound fraction of leptin in the metabolic syndrome. Obesity. 2003; 11:760-8.
[59]Cioffi JA, Shafer AW, Zupancie TJ. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nature Med.1996;2: 585-593.
[60]Hagemann D, Meier JJ, Gallwitz B, Schmidt WE. Appetite regulation by ghrelin—a novel neuro-endocrine gastric peptide hormone in the gut-brain-axis. Z Gastroenterol. 2003; 41: 929-36.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊
 
系統版面圖檔 系統版面圖檔